Trigantol

Quick links to important sections

Trigantol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trigantol

Quick Facts

Property Description
Active Ingredients Colecalciferol (D3), Retinol (A), alpha Tocoferol (E)
Form Oral Solution (Liquid Drops)
Pharmacological Class Vitamin and Mineral Combinations (ATC A11)
Common Type Fat-soluble Multivitamin
Origin Derived Essential Nutrients

What Type of Medicine is Trigantol and What is Its Form?

Trigantol is classified as a combination preparation and a multivitamin product, supplying three fat-soluble vitamins essential for human physiology. The active ingredients are formally grouped by the World Health Organization (WHO) under the Anatomical Therapeutic Chemical (ATC) Classification System group for Vitamins and Mineral Combinations (A11). The preparation is supplied as an oral solution or liquid drops, enabling administration through the oral route.

The core components of the medicine—Colecalciferol, Retinol, and alpha Tocoferol—are all lipid-soluble compounds. They are optimally absorbed in the presence of fats, which requires the pharmaceutical preparation to be formulated within a necessary lipid-based vehicle. This makes the composition chemically distinct from water-soluble vitamin forms, which are rapidly excreted and not stored in the body's fatty tissues.

Composition Profile: The Essential Fat-Soluble Vitamins

The preparation contains the triad of active substances: Colecalciferol (Vitamin D3), Retinol (Vitamin A), and alpha Tocoferol (Vitamin E). These molecules are defined as essential nutrients because the body cannot synthesize them in amounts sufficient for health maintenance, necessitating their acquisition through diet or supplementation. The presence of Colecalciferol establishes the product's fundamental link to calcium homeostasis, a mechanism where Vitamin D3 promotes the absorption of calcium in the gut.

General Purpose and Physiological Contribution

The function of Trigantol is to provide comprehensive nutritional support by ensuring adequate levels of these essential micronutrients, particularly in cases of deficiency risk or insufficient dietary intake. This type of formulation is often employed in a typical use scenario for patients with confirmed dietary malabsorption issues. For example, the crucial role of Vitamin E's antioxidant activity in defending cells against damage from oxidative stress is recognized in lipid biochemistry. The components collectively support bone health (via D3), the preservation of epithelial cell integrity and immune function (via A), and the vital free-radical scavenging action (via E).

Regulatory References

  1. NIH Information on Fat-Soluble Vitamins

What side effects are possible with Trigantol?

Possible side effects and safety information

Official regulatory documents classify adverse reactions to Trigantol (Nitroglycerin/Glyceryl Trinitrate) primarily based on frequency and affected physiological systems. The majority of documented effects relate to the drug's action on blood vessels (vasodilation).

Classification Examples of Officially Documented Adverse Reactions
Very Common / Common Headache, dizziness, flushing (redness), and hypotension (low blood pressure). Headache is the most frequently reported event and may be particularly noticeable at the start of therapy.
Uncommon / Rare Syncope (fainting), drug rash, and exfoliative dermatitis.

These effects are grouped into System-Organ Classes, which include Nervous System Disorders, Vascular Disorders, Cardiac Disorders, and Gastrointestinal Disorders.

Regulatory Safety Notes and Restrictions

Serious Adverse Reactions are explicitly documented and include cases of severe and prolonged hypotension, which may lead to circulatory shock, and fainting (syncope). Paradoxical bradycardia (abnormally slow heart rate) is also noted in official product information.

Population-Specific Considerations exist for older adults, who are officially documented to have an increased susceptibility to hypotension and syncope. Additionally, safety has not been established for pediatric use.

Time-Related Patterns show that common effects like headache and flushing are more frequent at treatment initiation. Regulatory documents define significant safety restrictions, including the absolute contraindication for concurrent use with phosphodiesterase type 5 (PDE5) inhibitors due to the risk of life-threatening hypotension. Use is also restricted in patients with severe anemia or increased intracranial pressure.

Overdose and Emergency Response

Overdose with Trigantol (Nitroglycerin) primarily results in effects related to severe blood vessel dilation. The documented manifestations of overdosage include profound severe hypotension which may lead to dizziness, syncope, weakness, and a persistent throbbing headache. Other recognized clinical presentations include flushing, nausea, vomiting, confusion, and visual disturbances. The most serious outcomes described in regulatory documents are shock, circulatory collapse, and potentially death stemming from uncorrected hypotension.

Massive doses may cause methemoglobinemia, a serious hematologic toxicity indicated by cyanosis (bluish discoloration) and dark urine. Treatment for methemoglobinemia is specified as Methylene Blue. Official regulatory information mandates that urgent medical attention must be sought immediately if symptoms are severe, such as loss of consciousness or circulatory failure. Additionally, patients are instructed to seek medical help if chest pain persists after administering three doses within a 15-minute period.

Management procedures in a clinical setting focus on supportive care, including central volume expansion to manage severe hypotension. Continuous monitoring of blood pressure and heart rate is necessary. Specific population considerations note that patients with underlying renal disease or congestive heart failure may require invasive monitoring during overdose management.

Therapeutic Uses of Trigantol

What Trigantol Treats: Main Uses and Benefits

Trigantol (whose active ingredient is nitroglycerin or glyceryl trinitrate) is commonly used to address symptoms related to heightened physiological activity in the cardiovascular system, specifically focusing on angina pectoris (chest pain). Nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

This medication is applied in addressing symptom clusters that may become intense or disruptive in contexts where short-term symptomatic support is needed. Its use is relevant in clinical settings that involve acute or unstable symptom patterns, and it is also applied in situations where symptoms may intensify temporarily. This action assists with managing symptoms related to reduced oxygen supply and helps reduce the strain on the heart, which is relevant in conditions where functional stability becomes affected by temporary physiological imbalance. It is commonly used during phases when symptoms become more noticeable, or may be applied to help manage symptoms linked to anticipated physiological strain. By providing supportive relief, the treatment contributes to improved comfort and may help patients cope more steadily with symptom fluctuations. The goal is to provide support that helps ease the overall symptom burden.


Quick Fact: Supportive relief for Symptoms related to physical discomfort (Angina Pectoris)

Eligibility and Restrictions for Use

Official Eligibility Rules for Trigantol (Nitroglycerin)

Use of Trigantol is generally established for adult patients aged 18 years and older. However, regulatory agencies define specific population groups for whom the medicine is strictly contraindicated and must not be used.

Absolute Contraindications

The medicine is absolutely prohibited for patients who have known hypersensitivity to nitrates or are concurrently using a Phosphodiesterase-5 (PDE-5) inhibitor (such as sildenafil or tadalafil). Contraindications also include patients with severe anemia, increased intracranial pressure (ICP), circulatory failure or shock, and certain cardiac conditions like hypertrophic obstructive cardiomyopathy.

Population Restrictions

Safety and effectiveness are not established in the pediatric population, meaning the medicine is not recommended for children and adolescents. For pregnancy and lactation, use is generally not recommended due to limited data, and should only proceed if deemed essential.

Caution is also advised for use in patients with severe hepatic (liver) or renal (kidney) impairment, and those who are hypotensive or volume-depleted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Element Official Regulatory Description
Medicinal product categories with documented interactions Bile acid sequestrants, mineral oil (laxatives), hepatic enzyme inducers (e.g., anti-epileptics), thiazide diuretics, calcium supplements, phosphate supplements, and Vitamin K antagonists.
Specific interacting medicines (if explicitly listed) Cholestyramine, Phenytoin, Phenobarbital, Carbamazepine, Hydrochlorothiazide, Warfarin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interference with absorption, pharmacodynamic reinforcement of systemic effects, and altered vitamin metabolism via hepatic enzymes.
Timing-based interaction rules (if applicable) Administration of Trigantol must be separated by several hours (generally ge 2 hours before or ge 4 hours after) when co-administered with bile acid sequestrants or mineral oil to prevent reduced absorption.
Population-specific interaction notes (if applicable) None are typically documented in regulatory labels as independent, specific interaction cautions.
Interaction-related restrictions Co-administration is restricted for certain substances due to the risk of reduced systemic exposure of the fat-soluble vitamins or due to heightened risk of hypercalcemia/hyperphosphatemia or bleeding.

Interaction classifications (high-level)

Classification Official Regulatory Description
Interaction severity classification (as defined in official documents) Interactions range from those requiring mandatory separation of doses to prevent reduced efficacy (absorption interference) to those requiring risk management due to potential for additive effects (e.g., hypercalcemia, increased bleeding risk).
Regulatory basis (EMA / FDA / etc.) The information is based on government regulatory documentation including FDA DailyMed, EMA SmPC, and NIH/MedlinePlus monographs for the active substances.
Interaction-context constraints (as defined in official documents) Co-administration of the component vitamins with other highly dosed vitamin A, D, or E supplements is a constraint due to the increased risk of toxicity (hypervitaminosis).

Resulting interaction structure

Official interaction statements:

  • Co-administration with hepatic enzyme inducers accelerates the metabolism of Colecalciferol (D3), resulting in reduced systemic exposure.
  • The systemic effects of Vitamin K antagonists may be potentiated by high doses of Retinol (A) and alpha Tocoferol (E), increasing the risk of bleeding.
  • Co-administration with bile acid sequestrants or mineral oil reduces the intestinal absorption of all fat-soluble vitamins (A, D, E), decreasing their bioavailability.
  • Concomitant use with thiazide diuretics or calcium/phosphate supplements creates an additive pharmacodynamic effect that increases the risk of hypercalcemia.
  • The absorption of all fat-soluble vitamins is dependent on the presence of dietary fat, a functional requirement for exposure.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the interaction structure of Trigantol by outlining pharmacokinetic constraints, specifically those related to the absorption of fat-soluble vitamins and the hepatic clearance of Colecalciferol. The profile also includes pharmacodynamic reinforcement patterns that increase systemic effects, such as the additive risk of hypercalcemia when combined with calcium-affecting medicines. This structure exclusively details substances and product categories that officially modify the exposure or effect of the fat-soluble vitamins as stated in governmental labeling.

Mechanism of Action

How Trigantol Works


The mechanism of Trigantol is defined by three complementary pharmacodynamic domains that govern mineral balance, cellular defense, and tissue structure. The Colecalciferol ( D3) component undergoes metabolic activation to the ligand Calcitriol, which binds the Vitamin D Receptor (VDR). This receptor activation modulates gene transcription, leading to the upregulation of proteins that enhance the gastrointestinal absorption of calcium and phosphate. This action provides the mineral components utilized in bone matrix formation.


The alpha Tocoferol ( E) component exerts a direct, non-genomic function as a chain-breaking antioxidant integrated within cell membranes. Its mechanism involves scavenging highly reactive lipid-peroxyl radicals, effectively terminating the autocatalytic cascade of lipid peroxidation. This process preserves the structural and functional continuity of cellular membranes.


Finally, Retinol ( A) is converted to Retinoic Acid (RA), which binds the Retinoic Acid Receptors (RARs). This receptor activation regulates the transcription of genes governing epithelial cell differentiation and proliferation, which establishes the mucosal and skin barriers. Retinol also contributes to the formation of the visual photopigment Rhodopsin.

Dosage and Administration Information

How to Use Trigantol (Nitroglycerin)

The official guidelines for using Trigantol, which contains nitroglycerin, strictly follow protocols designed for rapid relief and prophylaxis of angina pectoris. The administration is characterized by short-term, intermittent use governed by strict time and dose limits established in regulatory documents.


Administration Scope

Instruction Domain Official Labeled Instruction
Route of administration: Primarily Sublingual (under the tongue) or Buccal (cheek and gum) to ensure quick absorption.
Dosing schedule: Acute Relief: One dose (e.g., 0.4 mg or 400 mcg) at symptom onset, repeatable every five minutes as needed, up to a maximum of three doses within a 15-minute period.
Timing and Position: Administered at rest, preferably in a sitting position. For prophylaxis, taken 5 to 10 minutes prior to anticipated physical activity.
Age-group rules: Older Adults: Caution is advised, typically starting at the low end of the dose range. Pediatric Patients: Standard dosage is not established.
Preparation: Sublingual forms must not be chewed, crushed, or swallowed, but allowed to dissolve completely for proper mucosal absorption.

Official Use Protocol

The protocol governs how the medication is managed during an acute episode. After the initial dose, the patient may repeat the administration every five minutes. The final instruction within the protocol dictates that if anginal discomfort continues after the third dose in 15 minutes, the patient must immediately seek professional medical care. This limited, intermittent usage pattern is mandated to manage acute events and prevent the development of drug tolerance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trigantol

This section provides a summary of the clinical research conducted on the medicine (identified as Nitroglycerin/Glyceryl Trinitrate) focusing on the evidence base for angina pectoris. The findings described relate to group patterns observed in studies and do not determine whether an individual will respond similarly.


Evidence for Acute Relief of Angina Symptoms

Research exploring short-term symptom changes was conducted using placebo-controlled Randomized Controlled Trials (RCTs). These studies were evaluated in adults experiencing acute episodes of chest discomfort. Researchers primarily focused on outcomes related to physical discomfort, measuring the time until symptom resolution and objective physiological markers during controlled stress testing. Findings describe patterns where measurements of symptom resolution were noted rapidly (within minutes) following administration. Research also described data points related to ischemic markers on the electrocardiogram during testing.


Evidence for Chronic and Prophylactic Management

Studies exploring long-term prevention were organized into Systematic Reviews and Meta-analyses of controlled trials. These trials monitored angina attack frequency and consumption rate of rescue medication over defined time intervals. Research so far indicates that studies focusing on chronic use monitored differences in attack frequency and rescue tablet consumption when the medicine was used intermittently over several weeks. Findings from exercise trials suggested that research described differences in functional capacity during the study period.


Research Gaps and Areas of Uncertainty

A key pattern reported across the evidence base is the development of tolerance, which research describes as an observed attenuation of measured response when the medicine was administered continuously. Evidence is limited regarding prognostic survival data and duration of patterns observed in trials beyond intermediate follow-up periods. Data are insufficient for certain groups, such as pediatric populations or those with complex, co-existing health conditions, meaning the results apply primarily to the studied adult populations. Research remains ongoing in areas where official scientific reviews indicate the evidence quality varies or where certainty remains low.

Frequently Asked Questions (FAQ)

Common questions about Trigantol (FAQ)

Q: How long does the effect of one dose of Trigantol last?

Official guidelines describe that the acute action of the nitroglycerin component is short-lived. This rapid effect is consistent with the medication's primary use for sudden symptoms. The administration protocol is characterized by intermittent use, where doses may be repeated every five minutes as needed during an episode.


Q: Can Trigantol affect my liver or kidney function?

Regulatory documents state that caution is advised for use in patients who have pre-existing severe hepatic (liver) or renal (kidney) impairment. While the product information does not list liver or kidney impairment as a common side effect, official warnings note that caution is advised for these patient groups.


Q: Can I take Trigantol with my blood pressure medicine?

The official product information lists that co-administration with certain blood pressure medicines, specifically thiazide diuretics, may increase the risk of hypercalcemia (high calcium levels). For specific medication combinations, official documents indicate that professional supervision may be required.


Q: Has there been much research on the long-term effects of Trigantol?

Official summaries indicate that while studies have examined intermediate outcomes, evidence regarding prognostic survival data and the duration of patterns beyond intermediate follow-up periods remains limited. The information is based on the data available to regulatory bodies.


Q: Can I take Trigantol if I have a history of heart issues?

Official regulatory documents list specific serious cardiac conditions, such as hypertrophic obstructive cardiomyopathy, as absolute contraindications for use. For other concurrent cardiovascular conditions, the use of the medicine necessitates consideration of the documented warnings and contraindications.


Q: What if Trigantol doesn't work for me?

The protocol for acute angina relief defines that if anginal discomfort persists after the third dose in 15 minutes, the next step involves seeking professional medical care. This limited, intermittent usage pattern is mandated in the regulatory protocol.


Q: What are the signs of an allergic reaction to Trigantol?

Known hypersensitivity to nitrates is listed as a contraindication in official documents. Documented adverse reactions that may relate to an immune response include drug rash and exfoliative dermatitis (a severe shedding of the skin).


Q: Is Trigantol a type of painkiller?

Trigantol is officially classified by health authorities as a multivitamin and a combination preparation for the relief of angina pectoris. It is not listed under the pharmacological class for general painkillers.


Q: Is feeling tired a common side effect of Trigantol?

While tiredness itself is not explicitly listed as a very common side effect, official information documents adverse effects on the nervous system, such as dizziness and headache.


Q: Does Trigantol cause weight gain?

Weight gain or changes are not listed among the officially documented common or very common adverse reactions in regulatory product information.


Q: What happens if I forget to take a dose of Trigantol?

Official patient information typically provides specific instructions for managing a missed dose. These documents often outline a protocol to resume the regular schedule rather than taking a double dose.


Q: Are there any foods or drinks I need to avoid while on Trigantol?

Regulatory documents indicate that the absorption of the vitamin components is dependent on the presence of dietary fat. While the label does not list specific foods to avoid, it does list medicinal substances that must be separated from Trigantol by several hours to prevent reduced vitamin absorption. For guidance on specific food or supplement combinations, the patient information leaflet provides details and directs patients to the appropriate resource.


Q: Can I drink alcohol while taking Trigantol?

Official regulatory documents for the nitroglycerin component indicate a risk of severe hypotension (very low blood pressure) caused by the additive vasodilatory effects when combined with alcohol.


Q: Are there any herbal supplements that interact with Trigantol?

The official product information explicitly documents interactions with high-dose vitamin A, D, or E supplements and specific drug classes. Official documents focus on specific drug categories, but caution is also documented regarding co-administration with other highly dosed supplements.


Q: Is Trigantol a controlled substance?

Official regulatory information, such as that provided by the DEA, indicates that Trigantol, based on its active ingredients, is not classified as a controlled substance under relevant regulatory schedules.


Q: How long does Trigantol stay in your system?

The nitroglycerin component has a very short half-life, meaning it is rapidly cleared from the bloodstream, typically within a few minutes. The fat-soluble vitamin components (A, D, E) are generally stored in the body's fatty tissues and are eliminated much more slowly.


Q: Does taking Trigantol require special monitoring or blood tests?

Official warnings mention that due to the Colecalciferol (Vitamin D3) component, monitoring of certain mineral levels, specifically calcium and phosphate, may be required during the course of treatment.


Q: Is Trigantol approved in [Country X]?

The product information and regulatory documents are based on the approval granted by the relevant authority in the jurisdiction where the product is supplied (e.g., FDA in the US or EMA in the European Union).


Q: Is Trigantol habit-forming?

Regulatory information indicates that Trigantol, based on its active ingredients, is not considered a habit-forming or dependence-producing medicine.


Q: Are there any warnings about driving or operating machinery while on Trigantol?

Official regulatory documents include a caution regarding driving or operating machinery if patients experience documented side effects such as dizziness or syncope (fainting).


Q: Is it normal for my stomach to feel upset when starting Trigantol?

Official product information lists Gastrointestinal disorders as a general system-organ class where adverse reactions may occur. While specific stomach upset is not explicitly listed as a common side effect, this general classification indicates that GI effects are documented.


Q: Is a generic version of Trigantol available?

Official product listings from regulatory bodies indicate that generic versions containing the same active ingredients as Trigantol are available in various markets.


Q: Can Trigantol affect my ability to concentrate?

Official documents document side effects on the nervous system, such as headache and dizziness. These documented effects should be considered in relation to tasks requiring concentration.


Q: What is the history of Trigantol's approval by the FDA/EMA?

The official regulatory documents, such as the FDA's approval history or the EMA's EPAR Summary, contain detailed information regarding the date and scientific basis of the product’s approval by the relevant authority.

How should Trigantol be stored and disposed of?

Storage and Disposal Requirements

Storing Trigantol (Nitroglycerin) correctly is essential to maintain its labeled potency due to its volatile nature. The medicine must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The regulatory labeling strictly requires that the product not be refrigerated or frozen, as extreme temperatures can reduce its effectiveness.

Trigantol must be kept in its original, tightly closed container, typically an amber glass vial, to protect it from light and moisture. As with all medications, it must be stored out of the sight and reach of children.

For disposal, unused or expired Trigantol must not be thrown into household trash or poured down a drain. It should be returned to a pharmacy or designated collection program in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trigantol found in:

A-Z Index: